This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
bdev:fda [2020/11/25 16:06] richard |
bdev:fda [2021/08/16 22:22] (current) |
||
---|---|---|---|
Line 1: | Line 1: | ||
====== FDA approval ====== | ====== FDA approval ====== | ||
- | |||
Hi Richard, | Hi Richard, | ||
+ | |||
+ | |||
+ | |||
+ | FDA response {{ : | ||
+ | |||
+ | |||
+ | FDA submission, [[https:// | ||
+ | |||
+ | |||
You should complete a full validation of the instrument with a SARS-CoV-2 assay . | You should complete a full validation of the instrument with a SARS-CoV-2 assay . | ||
Line 30: | Line 38: | ||
* [[https:// | * [[https:// | ||
* [[https:// | * [[https:// | ||
+ | |||
+ | |||
+ | |||
+ | ---- | ||
+ | |||
+ | |||
+ | ... Coming from [[https:// | ||
+ | |||
+ | As discussed in the EUA template, an EUA request for a POC test should include data to demonstrate that non-laboratory personnel can perform the test accurately in the intended use environment, | ||
+ | |||
+ | |||
+ | |||
+ | ---- | ||
+ | |||
+ | |||
+ | Please submit a PEUA using the template | ||
+ | |||
+ | |||
+ | In your PEUA package, the template (MS word document) outlining the following information about your specific device; including: | ||
+ | |||
+ | |||
+ | - A detailed description of your device | ||
+ | - The proposed Intended Use/ | ||
+ | - Protocols for any analytical, non-clinical, | ||
+ | - Description and results of all analytical, non-clinical, | ||
+ | - [Other information FDA would like to see – specific to this type of medical device product] | ||
+ | - Specific questions you would like addressed. | ||
+ | |||
+ | |||
+ | ---- | ||
+ | | ||
+ | [[https:// | ||
+ | |||
+ | |||
+ | **Are you interested in submitting a Pre-EUA for an IVD test for a pathogen with a current EUA declaration? | ||
+ | ** | ||
+ | |||
+ | * Email CDRH-EUA-Templates@fda.hhs.gov and request a copy of the most recent EUA review template relevant to your test. | ||
+ | * Please include a brief description of your IVD (target pathogen, device technology – assay based on molecular, antigen or antibody detection, etc.). | ||
+ | * After you receive the EUA review template, populate the draft template with the information and data that you currently have for your IVD test. | ||
+ | * Send the draft template back to FDA for review as a Pre-EUA submission using the instructions that are provided along with the EUA review template (which includes sending 1 hard copy and 1 electronic copy to the Document Control Center). | ||
+ | * The Pre-EUA review is a very interactive process. The draft review template is a shared “work-in-progress” document which you will populate with information and data about your test. FDA will review and provide feedback to you. | ||
+ | |||
+ | |||
+ | |||
+ | Here is the partially filled template [[https:// | ||
+ | |||
+ | |||
+ | |||
+ | ---- | ||
+ | |||
+ | |||
+ | If this is for over the counter, this is the correct template Template for Manufacturers of Molecular and Antigen Diagnostic COVID-19 Tests for Non-Laboratory Use (July 29, 2020), however within this template it refers to the other templates for specific studies. | ||
+ | |||
+ | |||
+ | In your PEUA package, the template (MS word document) outlining the following information about your specific device; including: | ||
+ | |||
+ | * A detailed description of your device | ||
+ | * The proposed Intended Use/ | ||
+ | * Protocols for any analytical, non-clinical, | ||
+ | * Description and results of all analytical, non-clinical, | ||
+ | * [Other information FDA would like to see – specific to this type of medical device product] | ||
+ | * Specific questions you would like addressed. | ||
+ | |||
+ | | ||
+ | |||
+ | |||